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Background: Hypertension, dyslipidemia, and hyperglycemia are major risk factors for vascular reti-
nopathy. The relationship between retinal thickness at the macular area and metabolic risk factors, as
well as visual impairment, in elderly patients before developing vascular occlusion needs to be
investigated.
Methods: In this prospective, case-control study, patients >60 years old, without objective visual
threatened ocular diseases or systemic abnormalities, except for hypertension, dyslipidemia or/and hy-
perglycemia, were included for measurement of retinal thickness at the macular area by optical coher-
ence tomography (OCT).
Results: Fifty-four patients were analyzed; 11 patients had no metabolic risk factors, 16 had one, 17 had
two, and 10 had three. There was no signiﬁcant difference in age, and full and outer retinal thickness, but
there was a signiﬁcantly lower inner retinal thickness at the parafoveal (p ¼ 0.0013) and perifoveal
(p ¼ 0.018) areas in patients with at least one metabolic risk factor. The superior (p ¼ 0.040) and inferior
(p ¼ 0.046) inner retina at the perifovea and superior (p ¼ 0.013) inner retinal thickness at the parafovea
were sensitive to metabolic abnormalities. Only patients with three factors had signiﬁcantly reduced best
corrected visual acuity (BCVA).
Conclusion: Elderly patients with metabolic risk factors had decreased inner retinal thickness at the para-
and perifoveal areas before retinal vascular diseases. Accelerated inner retinal degeneration occurred
prior to visual impairment.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Metabolic syndrome is a constellation of abnormalities in
metabolic homeostasis, including glucose intolerance, insulin
resistance, dyslipidemia, central obesity, and hypertension.1e3 The
worldwide increased prevalence of metabolic syndrome contrib-
uting to the mortality of cardiovascular diseases, has been a
major public health problem.4e7 It is known that retinal vascular
diseases, such as retinal artery occlusion, retinal vein occlusion,
diabetic retinopathy with vascular leakage, hemorrhage or neo-
vascularization, attack visual acuity complicated with irreversiblemology, Wan Fang Hospital,
Road, Taipei 116, Taiwan.
Wu), wh9801@yahoo.com.tw
e Ophthalmologic Society of Taiwvisual disturbance. Hypertension, dyslipidemia, and hyperglyce-
mia, are the most common risk factors for retinal vascular dis-
eases.8e10 Moreover, more metabolic risks are associated with the
higher incidence of diabetic complications,11 and diabetic patients
with concomitant metabolic syndrome suffer from a higher prev-
alence of macro- and microvascular diseases, including retinop-
athy.11,12 The above ﬁndings implicated the possible role of
metabolic risks in visual outcome.
Diabetes- or retinal vascular occlusion-related macular edema
leads to severe visual disturbance,13,14 and optical coherence to-
mography (OCT) provides a noninvasive approach to accurately
measure retinal thickness at macular areas.15,16 Increase in macular
thickness due to macular edema diagnosed by OCT has beenwidely
used in clinical ophthalmology.17,18 However, only a handful of in-
vestigations of the macular thickness in diabetic or vascular reti-
nopathy without macular edema have been reported.19e22 Inan. Published by Elsevier Taiwan LLC. All rights reserved.
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any sign of vasculopathy at the early stage of diabetic retinop-
athy.19e21 It has been reported that a signiﬁcant decrease in peri-
central retinal thickness could be detected by OCT in patients of
type 1 diabetes mellitus with early diabetic retinopathy,22 indi-
cating that progressive loss of thickness at the macular area
occurred before advanced retinopathy induced by hyperglycemia.
In fact, the relationship among retinal thickness, visual acuity
and metabolic risk factors has not been clearly established. The
purpose of this study is to investigate the effect of hypertension,
dyslipidemia and hyperglycemia on macular thickness in elderly
patients without retinal vascular diseases. In this study, patients
were divided into four groups according to their cumulative
metabolic risks. Full, inner and outer retinal thickness at the central
foveal, parafoveal and perifoveal areas, respectively, were
measured by OCT. Best corrected visual acuity (BCVA) in each group
was also analyzed.
2. Methods
2.1. Inclusion and exclusion criteria
An Institutional Review Board approval fromWan Fang Hospital,
Taipei Medical University was obtained prior to the commence-
ment of this study. Patients >60 years old, with or without meta-
bolic risk factors (hypertension, dyslipidemia, or hyperglycemia),
from the outpatient clinic of the department of ophthalmology atFig. 1. Illustration of retinal thickness measurement. The full sensory retina was divided into
the fovea (0e1 mm diameter from central fovea), parafovea (1e3 mm diameter from central
hemispheres were divided by the horizontal line crossing the central fovea, while the nasalWan Fang Hospital, were included for the measurement of macular
thickness by OCT and complete ophthalmic evaluation, including
BCVA measurement by an auto Ref/Keratometer (Nidek ARK-710A;
Nidek Co. Ltd, Gamagori-shi, Aichi, Japan), pneumotonometer
measurement of intraocular pressure (Nidek NT-2000, Nidek Co.
Ltd), corneal, anterior segment and lens evaluation under slit lamp
microscopy (Nidek SL-1600, Nidek Co. Ltd), and vitreous and eye
ground examination under pupil dilation by indirect microscopy
(Welch Allyn 12500; Welch Allyn Inc., Skaneateles Falls, NY, USA).
The metabolic risk factors were conﬁrmed by three independent
blood pressure measurements (Omron HEM-1000, Omron, Taipei,
Taiwan), blood tests, including fasting blood sugar (Beckman
Coulter, Inc., Brea, CA, USA), glycated hemoglobin (Tosoh, Tokyo,
Japan), triglyceride, total cholesterol, low-density lipoprotein and
high-density lipoprotein (Beckman Coulter) within 6 months.
Among these patients, anyone who suffered from a visual threat-
ened ocular disease, such as opaque cornea and vitreous, glaucoma,
cataract (nuclear color > grade 2 according to the lens opacities
classiﬁcation system III23 or any grade of cortical cataract and
posterior subcapsular cataract), uveitis, or any kind of choroidop-
athy, retinopathy (including diabetic retinopathy, age-related
macular degeneration, myopic retinopathy), retinal vascular oc-
clusion, retinal hemorrhage, vascular leakage, neovascularization,
optic neuropathy, as well as abnormality detectable on OCT, such as
macular/retinal edema, cystic lesion, neovascular lesions, and
macular hole, were excluded. Furthermore, patients with a history
of any kind of acute visual loss, or with a systemic abnormalitythe outer retina and inner retina. Retinal thickness at the macular area was divided into
fovea), and perifovea (3e5 mm diameter from central fovea). The superior and inferior
and temporal hemispheres were divided by the vertical line crossing the central fovea.
Table 1
The deﬁnition of metabolic risk factors in our study.
Risk factor (IDFa 2005)
Dyslipidemia Raised triglycerides 150 mg/dL (1.7 mmol/L) or speciﬁc
treatment for this lipid abnormality
Reduced HDLb
cholesterol
<40 mg/dL (1.03 mmol/L) in males
<50 mg/dL (1.29 mmol/L) in females
or speciﬁc treatment for this lipid
abnormality
Hypertension Systolic BPc 130 or diastolic BP 85 mmHg or treatment of
previously diagnosed hypertension
Hyperglycemia FPGd100mg/dL (5.6 mmol/L), or previously diagnosed type
2 diabetes
a IDF ¼ International Diabetes Federation.
b HDL ¼ high-density lipoprotein.
c BP ¼ blood pressure.
d FPG ¼ fasting plasma glucose.
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excluded. Patients with preexisting renal insufﬁciency unrelated to
metabolic risks were excluded.
2.2. Measurement of retinal thickness by OCT
Retinal thickness at the macular area was measured by RTVue-
100 Fourier-domain OCT (Optovue Inc., Fremont, CA, USA). The
protocol of the scan in this study was EMM5 with 0.90 seconds
duration, which covered a 6 mm  6 mm area of the macula, with
21 horizontal and 21 vertical scans. This data was used to render a
5mm 5mmmap, and could be segmented for presentation of the
inner, outer and full retina thicknessmaps. The full retinal thickness
was measured from the vitreoretinal interface (VRI) to the photo-
receptor inner segment/outer segment (IS/OS) junction, the outer
retinal thickness was from the IS/OS to the inner plexiform layer
(IPL), and the inner retinal thickness was from the IPL to the VRI, as
per the manufacturer’s instructions. The macular area was sepa-
rated into three concentric circles: the fovea (central circle, with a
diameter of 1 mm), the parafovea (inner diameter of 1 mm and
outer diameter of 3mm) and the perifovea (inner diameter of 3 mm
and outer diameter of 5 mm) (Fig. 1) according to the protocol of
EMM5.Fig. 2. Analysis of metabolic risks. (A) In this study, 24 patients suffered from hypertension
with hypertension (B), dyslipidemia (C) or hyperglycemia (D), patients were divided by the2.3. Deﬁnition of metabolic risks
Hypertension, hyperglycemia and dyslipidemia were identiﬁed
on the basis of the new deﬁnition of International Diabetes Feder-
ation (IDF) in 2005,2 which is summarized in Table 1. In this study,
patients were divided into four groups according to the number of
metabolic risk factors (0, 1, 2 and 3). Patients with no metabolic risk
factor (0) served as controls.
2.4. Statistical analyses
Statistical analysis was performed using the Statistical Package
for Social Science-10 software (SPSS Inc., Chicago, IL, USA).
A comparison of the differences in age, BCVA, and retinal thickness
in patients with and without metabolic risks was analyzed by the
student t test (p < 0.05 or p < 0.01). Data of age, BCVA, and retinal
thickness among the four groups were analyzed by analysis of
variance (ANOVA) with Tukey’s post-hoc tests at 95% conﬁdence
intervals. In the tables, different alphabet characters represent
different levels of signiﬁcance.
3. Results
Fifty-four patients (24 males, 30 females), aged 60 years to 89
years (mean age ¼ 70.8 years), were included in this study. Among
those patients, 11 had nometabolic risk factor (0 risk), 16 had one (1
risk), 17 had two (2 risks), and 10 had three metabolic risk factors (3
risks). Among all patients, 24 suffered from hypertension, 28 had
dyslipidemia, and 28 had hyperglycemia (Fig. 2A). The detailed
patient proﬁles are summarized in Table 2 and Fig. 2A.
In patients with hypertension, there were seven patients in the
one risk group (hypertension only), seven in the two risk group
(combination of hypertension and dyslipidemia or hyperglycemia)
and 10 in the three risk group (Fig. 2B). However, only three pa-
tients with dyslipidemia belonged to the one risk group, 15
belonged to the two risk group, and 10 belonged to the three risk
group (Fig. 2C). There were six hyperglycemic patients in the one
risk group, 12 in the two risk group, and 10 in the three risk group
(Fig. 2D). In all patients, the retinal thickness was measured by OCT.
As shown in Fig. 1, we collected data of full, inner and outer retinal
thickness at the macular area. Moreover, the macular area was
separated into three circles including the central fovea, the paraf-
ovea, and the perifovea., 28 patients had dyslipidemia and 28 patients had hyperglycemia. Among the patients
ir accumulated metabolic risk factors.
Table 2
Summary of patient data.
No. Gender OD/OS Age (y) BCVA (log/Mar) Risk factor
Hypertension Dyslipidemia Hyperglycemia
Total number ¼ 54
Male:Female ¼ 24:30
Mean age (y): 70.8  8.61
0 risks (n ¼ 11)
1 F OD 67 0.4 N N N
2 F OS 60 0.7 N N N
3 F OD 84 0.7 N N N
4 F OD 60 0.5 N N N
5 F OS 73 0.7 N N N
6 F OD 60 0.6 N N N
7 F OS 74 0.8 N N N
8 F OD 63 0.4 N N N
9 F OS 70 0.8 N N N
10 F OS 60 0.5 N N N
11 M OD 60 0.9 N N N
1 risk (n ¼ 16)
1 M OS 86 0.3 Y N N
2 M OD 79 0.5 Y N N
3 M OS 79 0.4 N N Y
4 M OD 70 0.6 Y N N
5 F OD 81 0.2 Y N N
6 F OS 81 0.2 N N Y
7 M OD 76 0.4 N N Y
8 F OS 63 0.1 N Y N
9 M OD 63 0.6 N N Y
10 F OD 74 0.5 Y N N
11 F OD 67 0.5 N Y N
12 M OS 63 0.6 N N Y
13 F OS 67 0.3 N Y N
14 F OS 74 0.5 Y N N
15 F OD 66 0.9 N N Y
16 F OS 66 0.9 Y N N
2 risks (n ¼ 17)
1 F OD 68 0.3 N Y Y
2 M OD 67 0.9 N Y Y
3 M OS 70 0.4 Y Y N
4 M OD 65 0.3 N Y Y
5 M OD 77 0.9 N Y Y
6 M OS 85 0.4 N Y Y
7 M OS 61 0.2 Y N Y
8 M OS 81 0.5 Y N Y
9 F OS 76 0.4 Y Y N
10 F OD 64 0.5 Y Y N
11 M OS 64 0.7 N Y Y
12 F OD 74 0.5 N Y Y
13 M OS 67 0.7 N Y Y
14 M OD 70 0.4 Y Y N
15 F OS 64 0.4 Y Y N
16 M OD 64 0.3 N Y Y
17 F OS 74 0.5 N Y Y
3 risks (n ¼ 10)
1 F OD 81 0.3 Y Y Y
2 M OS 62 0.2 Y Y Y
3 F OS 88 0.2 Y Y Y
4 F OD 64 0.3 Y Y Y
5 F OS 64 0.3 Y Y Y
6 F OS 81 0.5 Y Y Y
7 M OS 89 0.4 Y Y Y
8 M OD 64 1.0 Y Y Y
9 M OD 62 0.2 Y Y Y
10 M OD 89 0.5 Y Y Y
BCVA ¼ best corrected visual acuity; OD ¼ right eye; OS ¼ left eye.
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thickness at the parafovea and perifovea
Patients without (0 risk) and with one or more metabolic risks
(1e3 risks) were compared; no difference in age (p ¼ 0.063) was
observed, but the BCVA was markedly decreased in patients with
metabolic risks (p¼ 0.016) (Table 3). It is known that the circulationof the inner retina is supplied by the retinal artery, while the outer
retina is supplied by the choroidal artery, so we ﬁrst compared the
difference of the full, inner and outer retinal thickness between
patients with and without metabolic risks. It was demonstrated
that metabolic risks did not affect the thickness of the full retina
and the outer retina at the fovea, parafovea and perifovea
(p > 0.05); however, the thickness of the inner retina at the
Table 3
Relationship between metabolic risks and retinal thickness.
Patient numbers Metabolic risk () Metabolic risk (þ) p
n ¼ 11 n ¼ 43
Age (y) 66.5  8.00 71.9  8.50 0.063
BCVA 0.64  0.169 0.46  0.220 0.016*
Full retinal thickness (mm)
Fovea 267.0  28.29 257.5  25.57 0.545
Parafovea 285.4  18.74 286.9  17.12 0.293
Perifovea 263.5  13.59 264.3  16.54 0.408
Inner retinal thickness (mm)
Fovea 79.8  16.64 78.3  15.80 0.780
Parafovea 110.1  11.79 99.2  12.79 0.013*
Perifovea 100.7  8.61 92.6  10.19 0.018*
Outer retinal thickness (mm)
Fovea 172.5  12.93 179.3  14.63 0.165
Parafovea 183.5  14.49 187.0  15.66 0.511
Perifovea 170.6  10.32 172.5  13.74 0.682
t test: * p < 0.05.
BCVA ¼ best corrected visual acuity.
Table 5
Relationship between metabolic risks and inner retinal thickness at the parafovea
and perifovea.
Patient numbers Metabolic risk () Metabolic risk (þ) p
n ¼ 11 n ¼ 43
Inner retinal thickness at parafovea (mm)
Superior hemisphere 112.4  13.11 99.9  14.71 0.013*
Inferior hemisphere 107.7  11.74 98.4  14.82 0.059
Superior temporal 113.1  15.63 100.5  14.95 0.017*
Superior nasal 116.2  14.27 101.7  14.61 0.005**
Inferior temporal 103.5  10.93 95.7  12.97 0.070
Inferior nasal 107.7  15.45 98.7  18.57 0.143
Inner retinal thickness at perifovea (mm)
Superior hemisphere 98.4  10.19 90.4  11.31 0.040*
Inferior hemisphere 103.3  8.80 94.7  13.14 0.046*
Superior temporal 95.2  8.52 89.2  13.19 0.090
Superior nasal 96.8  12.08 99.5  11.55 0.036*
Inferior temporal 107.7  10.25 87.0  13.48 0.063
Inferior nasal 103.3  12.07 94.4  13.49 0.053
t test: * p < 0.05; ** p < 0.01.
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central fovea (p ¼ 0.780), was signiﬁcantly decreased in patients
with metabolic risks (Table 3).
3.2. Loss of inner retinal thickness and BCVA were responses to
accumulative metabolic risks
Next, we analyzed whether accumulative metabolic risks
affected the BCVA or retinal thickness. In our study, there was no
signiﬁcant difference in age between the zero risk, one risk, two
risk, and three risk groups. The results in Table 4 demonstrated that
the BCVA was marginally decreased in patients with one or two
metabolic risks (level ab), and was only markedly decreased in
patients with three metabolic risks (level b) (ANOVA, p < 0.05). As
shown in Table 3, accumulative metabolic risks did not alter the full
and outer retinal thickness at the entire macular area. However, for
patients with one or twometabolic risks, a decrease in inner retinal
thickness could be found either at the perifovea or the parafovea;
for patients with three metabolic risks, a signiﬁcant loss of inner
retinal thickness occurred both at the parafovea (level b) and the
perifovea (level b) (Table 4) (ANOVA, p < 0.05).
3.3. Superior inner retina was sensitive to hypertension,
hyperglycemia and dyslipidemia
The inner retinawas further divided into the superior, or inferior
hemispheres, or the quadrisphere, based on the superior andTable 4
Effect of accumulative metabolic risks on best corrected visual acuity (BCVA) and inner
Patient numbers 0 risks 1 risk
n ¼ 11 n ¼ 16
Age (y) 66.5  8.00(a) 72.2  7.5
BCVA 0.64  0.150(a) 0.47  0.2
Full retinal thickness (mm)
Fovea 267.0  28.29(a) 267.0  28
Parafovea 285.4  18.74(a) 285.4  18
Perifovea 263.5  13.59(a) 263.5  13
Inner retinal thickness (mm)
Fovea 79.8  16.64(a) 86.0  18
Parafovea 110.1  11.79(a) 100.5  14
Perifovea 100.7  8.61(a) 93.2  8.7
Outer retinal thickness (mm)
Fovea 172.5  12.93(a) 181.1  17
Parafovea 183.5  14.49(a) 185.1  16
Perifovea 170.6  10.32(a) 170.4  12
ANOVAwith Tukey’s post-hoc tests at 95% conﬁdent intervals; different characters represe
patients among 0, 1, 2, and 3 risks groups, level “b” represents level signiﬁcantly lowerinferior divisions of retinal artery. Analysis of the inner retinal
thickness at the parafovea showed that the superior inner retina
(p ¼ 0.013) was more sensitive to metabolic damage than the
inferior inner retina (p ¼ 0.059), and a similar appearance could be
observed at the perifoveal area (Table 5). In response to accumu-
lative metabolic damage, patients with one metabolic risk showed
a marginal decrease in the superior inner retinal thickness at the
parafovea (level ab), while patients with two or three metabolic
risks showed a signiﬁcant loss of their superior inner retinal
thickness at the parafovea (Table 6). In comparison to the parafo-
vea, a loss of superior inner retinal thickness in response to accu-
mulative metabolic damage was not remarkable at the perifovea
(Table 6).
3.4. Medication controlling the metabolic risk factors did not alter
the inner retinal thickness at the parafovea
For patients with one, two, and three metabolic risks, those
under goodmedical control were deﬁned as the well control group.
Patients who received unsatisfactory medication, or who were
without medication, were deﬁned as the poor control group. Poor
control groups were further divided into two or three groups
depending on the uncontrolled metabolic risk numbers. Among the
16 patients with one metabolic risk, the mean inner parafovea
retinal thickness of the 10 well control cases was 97.9  11.17 mm
versus 98.33  17.76 mm for the six poor control cases (Fig. 3A).retinal thickness.
2 risks 3 risks
n ¼ 17 n ¼ 10
2(a) 70.1  6.78(a) 74.4  12.16(a)
27(ab) 0.49  0.203(ab) 0.39  0.242(b)
.29(a) 250.8  23.69(a) 253.9  21.42(a)
.74(a) 290.8  13.05(a) 282.9  20.74(a)
.59(a) 267.1  18.45(a) 261.1  18.35(a)
.17(a) 73.3  11.83(a) 74.5  14.05(a)
.03(ab) 98.6  13.46(b) 98.0  10.38(b)
7(b) 92.5  12.50(ab) 91.6  8.78(b)
.22(a) 177.7  14.84(a) 179.4  10.09(a)
.93(a) 190.1  16.02(a) 184.8  13.44(a)
.29(a) 176.4  15.79(a) 169.1  11.65(a)
nt different levels of signiﬁcance. Comparison of retinal thickness at the same area in
than level “a”, while level “ab” indicates level in between levels “a” and “b”.
Table 6
Effect of accumulative metabolic risks on inner retinal thickness at the parafovea and perifovea.
Patient numbers 0 risks 1 risk 2 risks 3 risks
n ¼ 11 n ¼ 16 n ¼ 17 n ¼ 10
Inner retinal thickness at parafovea (mm)
Superior hemisphere 112.4  13.11(a) 101.0  15.46(ab) 98.1  17.56(b) 100.5  7.55(b)
Inferior hemisphere 107.7  11.74(a) 99.8  13.98(ab) 99.0  16.19(ab) 95.3  14.78(b)
Superior temporal 113.1  15.63(a) 101.1  15.74(ab) 99.9  21.19(b) 101.4  9.38(ab)
Superior nasal 116.2  14.27(a) 104.2  17.12(ab) 100.4  14.62(b) 99.8  10.44(b)
Inferior temporal 103.5  10.93(a) 97.3  11.86(a) 95.1  14.92(a) 94.2  12.15(a)
Inferior nasal 107.7  15.45(a) 99.0  15.93(a) 99.9  21.19(a) 96.1  19.46(a)
Inner retinal thickness at perifovea (mm)
Superior hemisphere 98.4  10.19(a) 89.9  9.82(b) 88.7  14.55(ab) 94.3  6.11(ab)
Inferior hemisphere 103.3  8.80(a) 96.4  9.14(ab) 96.5  15.56(ab) 89.5  13.75(b)
Superior temporal 95.2  8.52(a) 88.4  10.66(a) 86.7  17.18(a) 94.9  6.98(a)
Superior nasal 96.8  12.08(a) 101.3  11.64(ab) 99.2  11.65(ab) 97.2  11.99(b)
Inferior temporal 107.7  10.25(a) 86.6  10.00(b) 88.6  17.56(ab) 85.0  11.11(b)
Inferior nasal 103.3  12.07(a) 96.1  11.68(ab) 95.5  13.65(ab) 89.9  16.15(b)
ANOVAwith Tukey’s post-hoc tests at 95% conﬁdent intervals; different characters represent different level of signiﬁcance. Comparison of retinal thickness at the same area in
patients among 0, 1, 2, and 3 risks groups, level “b” represents level signiﬁcantly lower than level “a”, while level “ab” indicates level in between levels “a” and “b”.
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parafovea retinal thickness of four well control cases was
92.2510.05 mm; it was 99.1116.32 mm in nine patients with one
abnormalmetabolic proﬁle, and 1047.87 mm in four patients with
two abnormal metabolic proﬁles (Fig. 3B). No one in the well
medical control group was in the three risk group (10 cases); two
had one abnormal metabolic proﬁle, with an inner parafovea
retinal thickness of 87.5  16.26 mm, three had two abnormal
metabolic proﬁles, with an inner parafovea retinal thickness of
96.33  5.77 mm, and ﬁve had three abnormal metabolic proﬁles,Fig. 3. Analysis of inner retinal thickness at the parafovea and impact of medical control. Am
factor numbers: (A) 16 patients with one metabolic risk; (B) 17 patients with two metabolic r
inner retinal thickness at the parafovea. There was no signiﬁcant difference in inner retinal t
one, two or three risks, respectively (p > 0.05). The well control group was deﬁned as patien
deﬁned as patients who had "n" abnormal metabolic proﬁle(s) with or without medicationwith an inner parafovea retinal thickness of 102.6  8.50 mm.
Analysis of inner retinal thickness at the parafovea showed no
signiﬁcant difference between the well control group and the poor
control group(s) (p > 0.05).
4. Discussion
For the ﬁrst time, we demonstrated the correlation of metabolic
risk factors and inner retinal thickness at the macular area. It would
therefore be important to routinely measure the inner retinalong 54 patients with metabolic risks, three groups were divided by their metabolic risk
isks; and (C) 10 patients with three metabolic risks. Fig. 3AeC illustrated the individual
hickness between the well control group and the poor control group(s) in patients with
ts with normal metabolic proﬁle under medication and the poor control group (n) was
.
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ﬁndings under indirect fundoscopy. We found that impaired
metabolic homeostasis speciﬁcally affected the inner retina, but not
the outer retina, at the parafovea and perifovea, and superior inner
retinal loss at the parafovea was more sensitive than inferior inner
retina. The central fovea was relatively spared metabolic injury.
Moreover, the severity of inner retinal loss was response to accu-
mulative metabolic damage, which occurred earlier than visual
disturbance.
It is well established that the pathophysiology of metabolic
syndrome, such as hypertension, dyslipidemia, and hyperglycemia,
is a vasculopathy in nature.24e27 Patients with metabolic risk fac-
tors had an increased risk of retinopathy.28 It has been reported that
metabolic syndrome is associated with endothelial dysfunction,
inﬂammation,29 and impaired retinal vasculature.26 In the human
retina, the inner retina is supplied by the retinal artery, with a direct
holangiotic vascular pattern, while the outer retina is supplied by
numerous anastomotic choroidal vessels.30,31 In this study, the in-
ner retinal thickness was selectively affected by impairedmetabolic
homeostasis (Table 3), suggesting that the retinal artery is more
sensitive to metabolic abnormality than the choroidal artery.
Different from retinal circulation, choroidal circulation constantly
keeps a high blood ﬂow to protect eye tissues from thermal injury
and to regulate retinal oxygenation.32 This may explain why
choroidal vessels are relatively more resistant to metabolic prob-
lems. Therefore, the change of inner retinal thickness was one of
the sequelae of impaired metabolic homeostasis that manifested
prior to retinal hemorrhage, vascular leakage, narrowing of the
artery, and vascular occlusion.
In this study, the number of metabolic risk factors was associ-
ated with the progression of inner retina loss at the parafovea and
perifovea (Table 4). Apoptosis of retinal neuroglial tissue, especially
at the parafovea, occurred in the early phase of diabetic retinopathy
and was associated with impaired retinal function.19e21 Retinal
neuroglial cells at the parafovea were the most abundant, with the
greatest thickness in the retina. In the current study, we demon-
strated that in hyperglycemic patients without diabetic retinop-
athy, and in patients with hypertension or dyslipidemia, loss of
inner retinal thickness at the parafovea and perifovea can also be
observed (Table 3). Compared to superior and inferior inner retinal
thickness, we found that the selective superior hemisphere at the
parafovea and both the superior and inferior hemisphere at the
perifovea were affected by metabolic injury (Table 4), indicating
that the metabolic syndrome-related microvascular change in the
superior branch of the retinal artery induced an initial loss of
neuroglial cells in the inner retina.
It was noteworthy that in the inner retina, at the macular area,
the central fovea (Fig. 1) was spared metabolic injury, and visual
disturbance was not signiﬁcant, except in patients with three
metabolic risks (Table 3). We suggested that the fovea was insen-
sitive to the chronic change of retinal microvascular abnormalities,
which might be contributed to by avascular characteristics and the
lack of inner retinal layer at the central fovea.
In this study, 17 of 24 hypertensive patients, 25 of 28 dyslipi-
demic patients and 22 of 28 hyperglycemic patients had the other
one or two metabolic risks (Fig. 2), which illustrated that
concomitant hypertension, dyslipidemia and hyperglycemia are
very common. Additionally, the association between dyslipidemia
and hypertension or hyperglycemia was relatively high (Fig. 2C).
The mechanisms of howmetabolic risk factors interacted with each
other and regulated the inner retinal thickness at the parafovea and
perifovea should be further investigated.
We also found that inner retinal thickness at the parafovea
did not correlate to medical control of metabolic risks. The irre-
versible damage of retinal neuron degeneration may one of theexplanations for our ﬁnding. The limited number of cases, as well as
mislabeling a patient who had a ﬂuctuating blood sugar level as
being in thewell control group, may also affect the interpretation in
this study.
There were some limitations of our study due to the limited
sample size: (1) the effects of medications for controlling metabolic
risk factors; (2) the duration or severity of hypertension, dyslipi-
demia, or hyperglycemia on retinal thickness; (3) factors other than
metabolic risks may affect the blood supply of the retina. The
relationship between the severity of metabolic syndrome and
macular degeneration warrants a further large-scale longitudinal
investigation in the future.
It is well established that the severity of diabetic nephropathy
was associated with a worsening of diabetic retinopathy.33 In this
study, we observed a positive correlation between accumulative
metabolic risks and the severity of abnormal serum creatinine
levels in some patients (3 patients had an abnormal serum creati-
nine level in the 2 risk group,1 patient had received hemodialysis in
the 3 risk group), but the relationship between abnormal serum
creatinine level and retinal thickness could not be concluded, due
to the limited number of cases.
Taken together, there was a signiﬁcant decrease in inner retinal
thickness at the parafovea and perifovea in patients with metabolic
risk factors, while the fovea was relatively resistant to metabolic
injury. The severity of inner retina loss was associated with the
accumulated metabolic risk factors. Visual impairment induced by
metabolic abnormality was less sensitive than inner retina loss at
the perifovea and parafovea. Thus, measurement of inner retinal
thickness at the macular area was indispensable for a patient with
metabolic risk factors, but negative for retinopathy.
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